S&P Futures
4,224.00 +14.00 (+0.33%) Dow Futures
33,366.00 +106.00 (+0.32%) Nasdaq Futures
13,453.75 +61.75 (+0.46%) Russell 2000 Futures
1,976.40 +6.90 (+0.35%) Crude Oil
91.80 -0.13 (-0.14%) Gold
1,804.30 -9.40 (-0.52%)
BioXcel Therapeutics, Inc. (BTAI)
After hours:
Chart Events
Performance Outlook
| Previous Close | 15.36 |
| Open | 15.76 |
| Bid | 14.81 x 900 |
| Ask | 15.58 x 1000 |
| Day's Range | 14.61 - 15.79 |
| 52 Week Range | 8.80 - 36.49 |
| Volume | |
| Avg. Volume | 533,106 |
| Market Cap | 419.777M |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.11 |
| Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 50.64 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BTAI
Related Research
- BioXcel Therapeutics, Inc.Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.RatingFair ValueEconomic Moat14 hours agoArgus Research
- GlobeNewswire
BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights
Commercially launched IGALMI™ (dexmedetomidine) sublingual film for the acute treatment of agitation in bipolar I or II disorder and schizophrenia in adult patients SERENITY III pivotal trial evaluating at-home use of BXCL501 for the acute treatment of agitation in bipolar and schizophrenia patients planned to initiate in 2H 2022 following recent Type B meeting with FDA Top-line data from TRANQUILITY II pivotal trial for agitation associated with Alzheimer’s disease expected in 1H 2023; TRANQUIL
- GlobeNewswire
BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference
NEW HAVEN, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Matt Wiley, Chief Commercial Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 a
- GlobeNewswire
BioXcel Therapeutics Announces NIH NIDA Grant to Columbia University to Support Further Studies of BXCL501 (Sublingual Dexmedetomidine) for Treating Opioid Withdrawal
Multi-year-funded award to support a 160-patient, randomized-controlled study in patients undergoing opioid withdrawal treatment Over 142 million opioid prescriptions dispensed in the U.S. in 20201 More than 1.7 million people in the U.S. suffered from substance use disorders related to prescription opioid pain relievers in 20161 NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelli
